Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 44% Though Its Price And Business Still Lag The Industry
Organogenesis Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Express News | Organogenesis Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Organogenesis Holdings Inc (ORGO) Q1 2025 Earnings Call Highlights: Navigating Market ...
Express News | Organogenesis Holdings Affirms FY2025 Sales Guidance of $480.00M-$535.00M Vs $488.25M Est
Organogenesis Hldgs Q1 Adj. EPS $(0.11) Misses $(0.06) Estimate, Sales $86.70M Miss $90.77M Estimate
12 Health Care Stocks Moving In Thursday's After-Market Session
Organogenesis: Q1 Earnings Snapshot
Organogenesis | 10-Q: Quarterly report
Organogenesis | 8-K: Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
Express News | Organogenesis Q1 Net Income USD -18.8 Million
Express News | Organogenesis Q1 Adjusted Net Income USD -13.4 Million
Press Release: Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
Organogenesis Holdings 1Q Loss $18.8M >ORGO
Earnings Preview: ORGO to Report Financial Results Post-market on May 08
Organogenesis | 10-K/A: Annual report (Amendment)
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access With High Quality Evidence of Effectiveness
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Further Weakness as Organogenesis Holdings (NASDAQ:ORGO) Drops 10% This Week, Taking Three-year Losses to 50%